肿瘤浸润淋巴细胞比例对乳腺癌新辅助化疗疗效的预测作用

发布时间：2018-05-02 11:42

本文选题：乳腺癌 + 肿瘤浸润淋巴细胞　；参考：《中国肿瘤临床》2017年23期

【摘要】：目的:评价乳腺癌患者行新辅助化疗前穿刺标本中的肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TIL)比例与术后病理评估疗效之间的关系。方法:收集2015年11月至2017年4月156例于天津医科大学肿瘤医院行乳腺肿物穿刺后病理证实为浸润性乳腺癌,并行新辅助化疗及手术的女性患者的临床资料。计算穿刺标本中TIL比例,并分为高、中、低组,利用组织病理学评价标准评估新辅助化疗疗效并分析两者的相关性。结果:新辅助化疗总有效率为78.2%(122/156),高TIL比例组的新辅助化疗有效率高于低TIL比例组(P0.01),激素受体阴性乳腺癌的TIL比例明显高于激素受体阳性乳腺癌(P0.01)。新辅助化疗疗效仅与TIL比例相关,与激素受体状态、HER-2受体状态、Ki-67阳性细胞比例无相关性。结论:乳腺癌穿刺标本中的TIL比例是预测乳腺癌新辅助化疗疗效的独立因子,TIL比例较高的乳腺癌患者的新辅助化疗疗效常更佳。
[Abstract]:Objective: to evaluate the relationship between the proportion of tumor infiltrating lymphocytes (infiltrating lymphocytes) in breast cancer patients before neoadjuvant chemotherapy and the postoperative pathological evaluation. Methods: the clinical data of 156 female patients with invasive breast cancer confirmed by pathology after breast tumor puncture and neoadjuvant chemotherapy and surgery were collected from November 2015 to April 2017 in the Cancer Hospital of Tianjin Medical University. The proportion of TIL in puncture specimens was calculated and divided into high, middle and low groups. Histopathological evaluation criteria were used to evaluate the efficacy of neoadjuvant chemotherapy and to analyze the correlation between the two. Results: the total effective rate of neoadjuvant chemotherapy was 78.2 / 1560.The effective rate of neoadjuvant chemotherapy in the high TIL group was higher than that in the low TIL group, and the TIL rate in the steroid-receptor negative breast cancer was significantly higher than that in the steroid-receptor-positive breast cancer. The effect of neoadjuvant chemotherapy was only related to the proportion of TIL, but not to the proportion of Ki-67 positive cells in the steroid receptor state of HER-2 receptor. Conclusion: the proportion of TIL in breast cancer samples is an independent factor for predicting the effect of neoadjuvant chemotherapy in breast cancer patients with higher proportion of til.
【作者单位】：天津医科大学肿瘤医院乳腺肿瘤一科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心乳腺癌防治教育部重点实验室;
【分类号】：R737.9

【相似文献】